Biology subjects

Lalansingh, C. M.

Publications and source records attributed to Lalansingh, C. M..

4 recordsLinked to original sources

bioRxiv2018

HPCI: A Perl module for writing cluster-portable bioinformatics pipelines

BackgroundMost biocomputing pipelines are run on clusters of computers. Each type of cluster has its own API (application programming interface). That API defines how a program that is to run on the cluster must request the submission, content and monitoring of jobs to be run on the cluster. Sometimes, it is desirable to run the same pipeline on different types of cluster. This can happen in situations including when:\n\nO_LIdifferent labs are collaborating, but they do not use the same type of cluster\nC_LIO_LIa pipeline is released to other labs as open source or commercial software\nC_LIO_LIa lab has access to multiple types of cluster, and wants to choose between them for scaling, cost or other purposes\nC_LIO_LIa lab is migrating their infrastructure from one cluster type to another\nC_LIO_LIduring testing or travelling, it is often desired to run on a single computer\nC_LI\n\nHowever, since each type of cluster has its own API, code that runs jobs on one type of cluster needs to be re-written if it is desired to run that application on a different type of cluster. To resolve this problem, we created a software module to generalize the submission of pipelines across computing environments, including local compute, clouds and clusters.\n\nResultsHPCI (High Performance Computing Interface) is a Perl module that provides the interface to a standardized generic cluster.\n\nWhen the HPCI module is used, it accepts a parameter to specify the cluster type. The HPCI module uses this to load a driver HPCD:: . This is used to translate the abstract HPCI interface to the specific software interface.\n\nSimply by changing the cluster parameter, the same pipeline can be run on a different type of cluster with no other changes.\n\nConclusionThe HPCI module assists in writing Perl programs that can be run in different lab environments, with different site configuration requirements and different types of hardware clusters. Rather than having to re-write portions of the program, it is only necessary to change a configuration file.\n\nUsing HPCI, an application can manage collections of jobs to be runs, specify ordering dependencies, detect success or failure of jobs run and allow automatic retry of failed jobs (allowing for the possibility of a changed configuration such as when the original attempt specified an inadequate memory allotment).

bioinformatics↗

bioRxiv2018

Accurate Reference-Free Somatic Variant-Calling by Integrating Genomic, Sequencing and Population Data

The detection of somatic single nucleotide variants (SNVs) is critical in both research and clinical applications. Studies of human cancer typically use matched normal (reference) samples from a distant tissue to increase SNV prediction accuracy. This process both doubles sequencing costs and poses challenges when reference samples are not readily available, such as for many cell-lines. To address these challenges, we created S22S: an approach for the prediction of somatic mutations without need for matched reference tissue. S22S takes underlying sequence data, augments them with genomic background context and population frequency information, and classifies SNVs as somatic or non-somatic. We validated S22S using primary tumor/normal pairs from four tumor types, spanning two different sequencing technologies. S22S robustly identifies somatic SNVs, with the area under the precision recall curve reaching 0.97 in kidney clear cell carcinoma, comparable to the best tumor/normal analysis pipelines. S22S is freely available at http://labs.oicr.on.ca/Boutros-lab/software/s22s.

bioinformatics↗

bioRxiv2018

Creating Standards for Evaluating Tumour Subclonal Reconstruction

Tumours evolve through time and space. Computational techniques have been developed to infer their evolutionary dynamics from DNA sequencing data. A growing number of studies have used these approaches to link molecular cancer evolution to clinical progression and response to therapy. There has not yet been a systematic evaluation of methods for reconstructing tumour subclonality, in part due to the underlying mathematical and biological complexity and to difficulties in creating gold-standards. To fill this gap, we systematically elucidated the key algorithmic problems in subclonal reconstruction and developed mathematically valid quantitative metrics for evaluating them. We then created approaches to simulate realistic tumour genomes, harbouring all known mutation types and processes both clonally and subclonally. We then simulated 580 tumour genomes for reconstruction, varying tumour read-depth and benchmarking somatic variant detection and subclonal reconstruction strategies. The inference of tumour phylogenies is rapidly becoming standard practice in cancer genome analysis; this study creates a baseline for its evaluation.

bioinformatics↗

bioRxiv2018

The Origins and Consequences of Localized and Global Somatic Hypermutation

Cancer is a disease of the genome, but the dramatic inter-patient variability in mutation number is poorly understood. Tumours of the same type can differ by orders of magnitude in their mutation rate. To understand potential drivers and consequences of the underlying heterogeneity in mutation rate across tumours, we evaluated both local and global measures of mutation density: both single-stranded and double-stranded DNA breaks in 2,460 tumours of 38 cancer types. We find that SCNAs in thousands of genes are associated with elevated rates of point-mutations, while similarly point-mutation patterns in dozens of genes are associated with specific patterns of DNA double-stranded breaks. These candidate drivers of mutation density are enriched for known cancer drivers, and preferentially occur early in tumour evolution, appearing clonally in all cells of a tumour. To supplement this understanding of global mutation density, we developed and validated a tool called SeqKat to identify localized \"rainstorms\" of point-mutations (kataegis). We show that rates of kataegis differ by four orders of magnitude across tumour types, with malignant lymphomas showing the highest. Tumours with TP53 mutations were 2.6-times more likely to harbour a kataegic event than those without, and 239 SCNAs were associated with elevated rates of kataegis, including loss of the tumour-suppressor CDKN2A. We identify novel subtypes of kataegic events not associated with aberrant APOBEC activity, and find that these are localized to specific cellular regions, enriched for MYC-target genes. Kataegic events were associated with patient survival in some, but not all tumour types, highlighting a combination of global and tumour-type specific effects. Taken together, we reveal a landscape of genes driving localized and tumour-specific hyper-mutation, and reveal novel mutational processes at play in specific tumour types.

cancer biology↗